Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

Luca Cantarini, Giuseppe Lopalco, Francesco Caso, Luisa Costa, Florenzo Iannone, Giovanni Lapadula, Maria Grazia Anelli, Rossella Franceschini, Cristina Menicacci, Mauro Galeazzi, Carlo Selmi, Donato Rigante

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Behçet's disease (BD) is a multi-systemic disorder of unknown etiology characterized by relapsing oral-genital ulcers, uveitis, and involvement of the articular, gastrointestinal, neurologic, and vascular systems. Although the primum movens of this condition remains unknown, a tangled plot combining autoimmune and autoinflammatory pathways has been hypothesized to explain its start and recurrence. In-depth analysis of BD pathogenetic mechanisms, involving dysfunction of multiple proinflammatory molecules, has opened new modalities of treatment: different agents targeting interleukin-1 have been studied in recent years to manage the most difficult and multi-resistant cases of BD. Growing experience with anakinra, canakinumab and gevokizumab is discussed in this review, highlighting the relative efficacy of each drug upon the protean BD clinical manifestations. Safety and tolerability of interleukin-1 antagonists in different doses have been confirmed by numerous observational studies on both large and small cohorts of patients with BD. In particular, the potential for Mycobacterium tuberculosis reactivation and tuberculosis development appears to be significantly lower with interleukin-1 blockers compared to tumor necrosis factor-α inhibitors, thus increasing the beneficial profile of this approach.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAutoimmunity Reviews
Volume14
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Disease Management
Interleukin-1
Tuberculosis
Safety
Oral Ulcer
Interleukin 1 Receptor Antagonist Protein
Uveitis
Mycobacterium tuberculosis
Nervous System
Observational Studies
Blood Vessels
Tumor Necrosis Factor-alpha
Joints
Recurrence
Pharmaceutical Preparations
Therapeutics

Keywords

  • Anakinra
  • Behçet's disease
  • Canakinumab
  • Gevokizumab
  • Interleukin-1
  • Tuberculosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. / Cantarini, Luca; Lopalco, Giuseppe; Caso, Francesco; Costa, Luisa; Iannone, Florenzo; Lapadula, Giovanni; Anelli, Maria Grazia; Franceschini, Rossella; Menicacci, Cristina; Galeazzi, Mauro; Selmi, Carlo; Rigante, Donato.

In: Autoimmunity Reviews, Vol. 14, No. 1, 2015, p. 1-9.

Research output: Contribution to journalArticle

Cantarini, L, Lopalco, G, Caso, F, Costa, L, Iannone, F, Lapadula, G, Anelli, MG, Franceschini, R, Menicacci, C, Galeazzi, M, Selmi, C & Rigante, D 2015, 'Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease', Autoimmunity Reviews, vol. 14, no. 1, pp. 1-9. https://doi.org/10.1016/j.autrev.2014.08.008
Cantarini, Luca ; Lopalco, Giuseppe ; Caso, Francesco ; Costa, Luisa ; Iannone, Florenzo ; Lapadula, Giovanni ; Anelli, Maria Grazia ; Franceschini, Rossella ; Menicacci, Cristina ; Galeazzi, Mauro ; Selmi, Carlo ; Rigante, Donato. / Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease. In: Autoimmunity Reviews. 2015 ; Vol. 14, No. 1. pp. 1-9.
@article{3410962e80344f558567aa6a9f3dd76c,
title = "Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh{\cc}et's disease",
abstract = "Beh{\cc}et's disease (BD) is a multi-systemic disorder of unknown etiology characterized by relapsing oral-genital ulcers, uveitis, and involvement of the articular, gastrointestinal, neurologic, and vascular systems. Although the primum movens of this condition remains unknown, a tangled plot combining autoimmune and autoinflammatory pathways has been hypothesized to explain its start and recurrence. In-depth analysis of BD pathogenetic mechanisms, involving dysfunction of multiple proinflammatory molecules, has opened new modalities of treatment: different agents targeting interleukin-1 have been studied in recent years to manage the most difficult and multi-resistant cases of BD. Growing experience with anakinra, canakinumab and gevokizumab is discussed in this review, highlighting the relative efficacy of each drug upon the protean BD clinical manifestations. Safety and tolerability of interleukin-1 antagonists in different doses have been confirmed by numerous observational studies on both large and small cohorts of patients with BD. In particular, the potential for Mycobacterium tuberculosis reactivation and tuberculosis development appears to be significantly lower with interleukin-1 blockers compared to tumor necrosis factor-α inhibitors, thus increasing the beneficial profile of this approach.",
keywords = "Anakinra, Beh{\cc}et's disease, Canakinumab, Gevokizumab, Interleukin-1, Tuberculosis",
author = "Luca Cantarini and Giuseppe Lopalco and Francesco Caso and Luisa Costa and Florenzo Iannone and Giovanni Lapadula and Anelli, {Maria Grazia} and Rossella Franceschini and Cristina Menicacci and Mauro Galeazzi and Carlo Selmi and Donato Rigante",
year = "2015",
doi = "10.1016/j.autrev.2014.08.008",
language = "English",
volume = "14",
pages = "1--9",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

AU - Cantarini, Luca

AU - Lopalco, Giuseppe

AU - Caso, Francesco

AU - Costa, Luisa

AU - Iannone, Florenzo

AU - Lapadula, Giovanni

AU - Anelli, Maria Grazia

AU - Franceschini, Rossella

AU - Menicacci, Cristina

AU - Galeazzi, Mauro

AU - Selmi, Carlo

AU - Rigante, Donato

PY - 2015

Y1 - 2015

N2 - Behçet's disease (BD) is a multi-systemic disorder of unknown etiology characterized by relapsing oral-genital ulcers, uveitis, and involvement of the articular, gastrointestinal, neurologic, and vascular systems. Although the primum movens of this condition remains unknown, a tangled plot combining autoimmune and autoinflammatory pathways has been hypothesized to explain its start and recurrence. In-depth analysis of BD pathogenetic mechanisms, involving dysfunction of multiple proinflammatory molecules, has opened new modalities of treatment: different agents targeting interleukin-1 have been studied in recent years to manage the most difficult and multi-resistant cases of BD. Growing experience with anakinra, canakinumab and gevokizumab is discussed in this review, highlighting the relative efficacy of each drug upon the protean BD clinical manifestations. Safety and tolerability of interleukin-1 antagonists in different doses have been confirmed by numerous observational studies on both large and small cohorts of patients with BD. In particular, the potential for Mycobacterium tuberculosis reactivation and tuberculosis development appears to be significantly lower with interleukin-1 blockers compared to tumor necrosis factor-α inhibitors, thus increasing the beneficial profile of this approach.

AB - Behçet's disease (BD) is a multi-systemic disorder of unknown etiology characterized by relapsing oral-genital ulcers, uveitis, and involvement of the articular, gastrointestinal, neurologic, and vascular systems. Although the primum movens of this condition remains unknown, a tangled plot combining autoimmune and autoinflammatory pathways has been hypothesized to explain its start and recurrence. In-depth analysis of BD pathogenetic mechanisms, involving dysfunction of multiple proinflammatory molecules, has opened new modalities of treatment: different agents targeting interleukin-1 have been studied in recent years to manage the most difficult and multi-resistant cases of BD. Growing experience with anakinra, canakinumab and gevokizumab is discussed in this review, highlighting the relative efficacy of each drug upon the protean BD clinical manifestations. Safety and tolerability of interleukin-1 antagonists in different doses have been confirmed by numerous observational studies on both large and small cohorts of patients with BD. In particular, the potential for Mycobacterium tuberculosis reactivation and tuberculosis development appears to be significantly lower with interleukin-1 blockers compared to tumor necrosis factor-α inhibitors, thus increasing the beneficial profile of this approach.

KW - Anakinra

KW - Behçet's disease

KW - Canakinumab

KW - Gevokizumab

KW - Interleukin-1

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84924272779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924272779&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2014.08.008

DO - 10.1016/j.autrev.2014.08.008

M3 - Article

VL - 14

SP - 1

EP - 9

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 1

ER -